另一篇全文
所在版块:心情闲聊 发贴时间:2020-04-30 11:27

用户信息
复制本帖HTML代码
高亮: 今天贴 X 昨天贴 X 前天贴 X 

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19

April 29, 2020 at 8:30 AM EDT

FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020--Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19. Gilead will share additional remdesivir data from the company’s open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

About Remdesivir

Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS. In vitro testing conducted by Gilead has demonstrated that remdesivir is active against the virus that causes COVID-19. The safety and efficacy of remdesivir for the treatment of COVID-19 are being evaluated in multiple ongoing Phase 3 clinical trials.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This statement includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. Remdesivir is an investigational drug that has not been approved by any regulatory authority, and it has not been demonstrated to be safe or effective for any use, including for the treatment of COVID-19. There is the possibility of unfavorable results from ongoing and additional clinical trials involving remdesivir and the possibility that Gilead may be unable to complete one or more of such trials in the currently anticipated timelines or at all. Further, it is possible that Gilead may make a strategic decision to discontinue development of remdesivir or that FDA and other regulatory authorities may not approve remdesivir, and any marketing approvals, if granted, may have significant limitations on its use. As a result, remdesivir may never be successfully commercialized. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.


.
欢迎来到华新中文网,踊跃发帖是支持我们的最好方法!

 相关帖子 我要回复↙ ↗回到正文
【其它话题】瑞德西韦数据出来了 乌贼的马甲   (184 bytes , 5359reads )
50% 的治愈率,random guess,用药一半能好,一半好不了 henryYang   (57 bytes , 9reads )
死亡率将说明一切 lgland   (0 bytes , 11reads )
显然这是希望的软肋 笑天   (31 bytes , 13reads )
看治愈率也行 lgland   (112 bytes , 13reads )
治愈率应该也是软肋 笑天   (46 bytes , 16reads )
可以看作两次实验 kusubudo   (58 bytes , 16reads )
歪个楼 有感而发 Tridenttt   (475 bytes , 20reads )
这个,去看这个 笑天   (52 bytes , 10reads )
Gilead成功了 -原来真的是政治 笑天   (135 bytes , 12reads )
PDF 这里 笑天   (70 bytes , 12reads )
不管结果如何 笑天   (18 bytes , 10reads )
主要结果 笑天   (58 bytes , 13reads )
OXFORD的说法 笑天   (209 bytes , 10reads )
各个高人都是牛人 rjm   (97 bytes , 10reads )
原来你在聊股票.... Calicocat   (14 bytes , 19reads )
股票和科学态度是两回事 笑天   (62 bytes , 13reads )
来了,结果自己看 笑天   (249 bytes , 22reads )
显然不符合常规的报告 笑天   (11 bytes , 12reads )
你弄错了,不是这个试验 快快跑   (833 bytes , 11reads )
比如tamiflu 对付流感这种。 Calicocat   (22 bytes , 13reads )
你帮某些懒人把数据链接都找全了 乌贼的马甲   (142 bytes , 11reads )
读了一下,这个就是最新 笑天   (32 bytes , 14reads )
另外两个也是最新的April 29, 2020 快快跑   (12 bytes , 8reads )
读吧 笑天   (39 bytes , 11reads )
火了,全文再此 笑天   (45766 bytes , 14reads )
另一篇全文 笑天   (11426 bytes , 10reads )
23号的报告(leaked)- 科学态度? 笑天   (30998 bytes , 4reads )
自己和自己比,5天和10天比 笑天   (113 bytes , 14reads )
副作用看起来也是有的 Calicocat   (39 bytes , 13reads )
我刚才搜了一下,才明白 笑天   (169 bytes , 6reads )
虽然我早已不需要做学问了 笑天   (60 bytes , 12reads )
佩服 chetang   (10 bytes , 14reads )
只能说五天non inferior 或者10天 non superior douknnowme   (0 bytes , 10reads )
这也是正面的表述,领导都喜欢这样的 笑天   (270 bytes , 5reads )
最新的数据不是双盲,是根据clinical trial得出来的 乌贼的马甲   (38 bytes , 12reads )
我猜测现在的重症患者没几个敢参加双盲的 乌贼的马甲   (38 bytes , 10reads )
同一天的柳叶刀 (4月29日) 笑天   (34 bytes , 13reads )
NIH使用金标准证明有效 快快跑   (216 bytes , 11reads )
你说的我同意,FDA本来就批了 -孤儿药的, 笑天   (4146 bytes , 26reads )
NIH的说法 笑天   (345 bytes , 9reads )
只有这个数据作为亮点 笑天   (842 bytes , 11reads )
可以帮国家和保险公司省不少钱 快快跑   (106 bytes , 16reads )
有道理,我只是在质疑它的科学基础 笑天   (346 bytes , 9reads )
外面也不是没有质疑的声音 笑天   (761 bytes , 10reads )
关于瑞德拉韦的背景资料-这个比较全 笑天   (202 bytes , 12reads )
其实有点同情gilead 笑天   (66 bytes , 9reads )
有错了 是 Ebola 笑天   (0 bytes , 11reads )
要是没副作用,拿来当预防的用也还不错 Calicocat   (26 bytes , 9reads )
我相信数据是真实的 笑天   (500 bytes , 10reads )
4月23号的报告 笑天   (718 bytes , 12reads )
数据说话,各自解读, 形势需要 笑天   (3935 bytes , 17reads )
Gilead server down 笑天   (55 bytes , 10reads )
都散了吧,这货就一爱崇洋舔美的。 18厘米的烦恼   (242 bytes , 10reads )
赞这个层主 ImHResIDeNt   (78 bytes , 11reads )
你这货又是哪一路的? 乌贼的马甲   (96 bytes , 15reads )
订单爆棚? 笑天   (58 bytes , 9reads )
我特么算是服了 茕茕白兔   (42 bytes , 24reads )
特效谈不上 alexwee   (43 bytes , 27reads )
建议了解一下吉利德公司先 rjm   (120 bytes , 18reads )
股神 Tridenttt   (63 bytes , 11reads )
看澳元今天怎么走的 笑天   (8 bytes , 10reads )
这个公司 Ke33   (51 bytes , 26reads )
前面中国也说了,效果肯定是有的,但不是特效,初期有效。 Calicocat   (412 bytes , 22reads )
同意你 宝狐   (41 bytes , 10reads )
当时双黄连股票还暴涨呢 Seabass   (8 bytes , 13reads )
有没有效,资本市场说明了一切 rjm   (104 bytes , 15reads )
对啊,有没有效时间会说明一切 乌贼的马甲   (296 bytes , 18reads )
世卫泄露的也是吉利德自己给的 笑天   (22 bytes , 14reads )
吉利德上报自己的数据给WHO 乌贼的马甲   (105 bytes , 14reads )
看新闻没觉得特别有效啊 Calicocat   (207 bytes , 21reads )
这个50%不是很理解 kusubudo   (45 bytes , 13reads )
是啊,没有对照组,很难说多有效 Calicocat   (80 bytes , 15reads )
编继续编 没有细节数据的新闻不是好新闻 功夫熊猫   (0 bytes , 16reads )
想看细节自己去找啊 乌贼的马甲   (22 bytes , 17reads )
呵呵 没有数据的文章多好编 功夫熊猫   (0 bytes , 20reads )
我也没强逼着让你信不是? 乌贼的马甲   (170 bytes , 17reads )
股票赚一笔我相信,这药有多神我不信 JeanGloria   (164 bytes , 16reads )
呵呵 列不列是一回事 列出来的数据可信不可信是另一回事 功夫熊猫   (23 bytes , 10reads )
你看,您太把自己当回事儿了不是 乌贼的马甲   (162 bytes , 10reads )
是的 女人衰老利器排行榜第一名就是懒 功夫熊猫   (10 bytes , 16reads )
那你可得多动一动了 乌贼的马甲   (8 bytes , 13reads )
泥奏凯 功夫熊猫   (12 bytes , 9reads )
不带中医玩,神药说你无效就无效 rjm   (44 bytes , 20reads )
在西医引入中国之前 nobodyknow   (32 bytes , 18reads )
是啊,电灯没有引进以来 pipi02   (43 bytes , 10reads )
张嘴就来 zamulano   (8 bytes , 40reads )